ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Immunogen (IMGN) Tops Q2 EPS by 4c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
August 2, 2019 6:38 AM EDTImmunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.29), $0.04 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $15.54 million versus the consensus estimate of $9.48 million.
Registration Study for Mirvetuximab Soravtansine in Ovarian Cancer on Track to Start by Year-EndFull Data from the Phase 3 FORWARD I Trial and Initial FORWARD II Triplet Data to be Presented at ESMORecommended Phase 2 Dose and Schedule for IMGN632 Determined; Combination and MRD+ Protocol... More